Online inquiry

IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15198MR)

This product GTTS-WQ15198MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Crohn's disease (CD), Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ15198MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12227MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ3667MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ3149MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA APT070
GTTS-WQ14336MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG7414
GTTS-WQ14723MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-19A
GTTS-WQ3828MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BCD-054
GTTS-WQ4805MR IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BT 5/9
GTTS-WQ1035MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-399
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW